Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Increased compatibility for cancer assays
September 2019
SHARING OPTIONS:

TUCSON, Ariz.—HTG Molecular Diagnostics Inc. has reintroduced two previously released assays, now for use with Thermo Fisher Scientific’s Ion Torrent Ion S5 next-generation sequencing platform: the HTG EdgeSeq DLBCL Cell of Origin Assay and the HTG EdgeSeq Lung Fusions RUO Assay. The former helps users determine the molecular sub-type of diffuse large B-cell lymphomas (DLBCL) via a gene expression-based classification system, while the latter measures and analyzes mRNA ALK gene fusion events in FFPE lung tumor specimens from patients with non-small cell lung cancer.
 
“Our sequencer-agnostic approach allows those customers who have made the investment in an NGS system to adopt our assays without having to invest in a new sequencing system,” remarked John Lubniewski, president and CEO of HTG. “We are thrilled to be the assay of choice for many of our customers and are committed to continuing to expand our menu to meet their needs.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.